Cleared Traditional

K061239 - EUROIMMUN ANTI-HSV-2 ELISA (IGG) AND ANTI-HSV-1 ELISA (IGG) KIT

K061239 is an FDA 510(k) clearance for EUROIMMUN ANTI-HSV-2 ELISA (IGG) AND AN..., manufactured by Euroimmun Us, LLC. The device is a Class 2 Microbiology device with product code MYF cleared through the Traditional 510(k) pathway after a 421-day FDA review.

K061239 · Euroimmun Us, LLC · Microbiology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Jun 2007
Decision
421d
Days
Class 2
Risk

K061239 is an FDA 510(k) clearance for the EUROIMMUN ANTI-HSV-2 ELISA (IGG) AND ANTI-HSV-1 ELISA (IGG) KIT. Classified as Enzyme Linked Immunosorbent Assay, Herpes Simplex Virus, Hsv-2 (product code MYF), Class II - Special Controls.

Submitted by Euroimmun Us, LLC (Boonton Township, US). The FDA issued a Cleared decision on June 28, 2007 after a review of 421 days - an unusually long review period, suggesting complex equivalence evaluation.

This device falls under the Microbiology FDA review panel, regulated under 21 CFR 866.3305 - the FDA microbiology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: High-complexity regulatory submission. Elevated predicate reliance profile. The extended review timeline suggests the FDA required additional documentation before confirming substantial equivalence - a pattern common in complex or first-of-kind Microbiology submissions.

View all Euroimmun Us, LLC devices

FDA 510(k) Submission Details - K061239

510(k) Number K061239 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received May 03, 2006
Decision Date June 28, 2007
Days to Decision 421 days
Submission Type Traditional
Review Panel Microbiology (MI)
Summary Statement
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
319d slower than avg
Panel avg: 102d · This submission: 421d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

MYF Device Classification - Class 2, Special Controls

Product Code MYF Enzyme Linked Immunosorbent Assay, Herpes Simplex Virus, Hsv-2
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 866.3305
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Microbiology devices follow this clearance model.

Regulatory Peers - MYF Enzyme Linked Immunosorbent Assay, Herpes Simplex Virus, Hsv-2

All 7
Devices cleared under the same product code (MYF) and FDA review panel - the closest regulatory comparables to K061239.
ADVIA Centaur Herpes-2 IgG
K181334 · Biokit, S.A. · Aug 2018
ZEUS ELISA HSV GG-2 IGG TEST SYSTEM
K103603 · Zeus Scientific, Inc. · May 2011
LIAISON HSV-2 TYPE SPECIFIC IGG ASSAY, CONTROL HSV-2 IGG
K081687 · DiaSorin, Inc. · Nov 2008
HSV-2 ELISA IGG, MODEL EL0920G
K993724 · Mrl Diagnostics · Feb 2000